Navigation Links
First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire/ -- On Thursday, January 31, General Hospital Vienna successfully completed its first Volumetric Modulated Arc Therapy (VMAT)* treatment. The hospital is one of the first in the world to carry out this innovative cancer treatment option.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

VMAT technology provides a simultaneous control of the linear accelerator gantry position and speed, the leaves and angle of the multileaf collimator and dose rate. This flexibility enables highly conformal cancer treatments, as well as optimal sparing of the healthy tissue around the target. In addition, VMAT significantly reduces patient treatment times, leading to greater patient comfort and stillness for a more efficient and precise treatment.

Dietmar Georg, Ph.D., head of the Division of Medical Radiation Physics at General Hospital Vienna (Medical University Vienna, Vienna, Austria) says the first patient was treated for glioblastoma, a serious brain tumor that was positioned near vital structures such as the brain stem and optical lenses and nerves. The treatment consisted of three non-coplanar VMAT arcs with collimator rotation. The entire treatment took just 10 minutes, including creation and evaluation of the patient's brain images and treatment positioning.

"This therapy is applied in very complex situations where the localization and form of the tumor requires tailored intensity modulated treatment," says Dr. Georg.

Elekta provides complete VMAT package

General Hospital Vienna used its existing Elekta Synergy(R) S system to perform the VMAT treatment, along with Elekta's next generation linear accelerator control software. Elekta's VMAT solution also includes ERGO++ treatment planning system for rotational therapy, and MOSAIQ(TM) image-enabled oncology Electronic Medical Records (EMR) system. This complete VMAT solution is now available in upgrades to existing Elekta accelerators.

General Hospital Vienna is the largest radiotherapy center in Austria, and treats approximately 3,000 radiotherapy patients per year. The capability to perform VMAT offers a tremendous advantage for the hospital and its patients, says Chief Medical Doctor Professor Richard Potter. "The new system will revolutionize tailored intensity modulated radiotherapy during the next decade. Very soon, not only head and neck lesions will be treated with VMAT, but also tumors in the lung, close to the cervical spine and in the pelvis."

"What I've seen so far is the possibility that we can, in the long term, treat more patients, because we have a more efficient workflow and much faster treatments," says Dr. Georg. "We are at the forefront of the leading radio- oncology hospitals in the world. VMAT will give us an enormous impetus both scientifically and in medical care."

*Elekta Volumetric Intensity Modulated Arc Therapy (VMAT) is pending regulatory approvals in certain markets, including 510(k) clearance in the US, and is not yet available for commercial sale in the US.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state-of-the-art tools to fight serious disease.

Elekta provides advanced clinical solutions and comprehensive management and information systems, as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery, as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With more than 2,000 employees globally, Elekta corporate headquarters are located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Nevro Corp. (NYSE: NVRO), a global medical device company ... chronic pain, today reported financial results for the three months ... 2016 Accomplishment & Highlights: Achieved revenue of ... 228% as reported, over the prior year U.S. ... over the prior year International revenue of ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, ... Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist by ... directory that recognizes local physicians and dentists who have earned high ratings and superior ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, ... the Minneapolis Home and Garden Show which is being held February 24 through 26 ... is the Minneapolis Convention Center. , From its broad line of sit stand ...
Breaking Medicine News(10 mins):